Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Lenvatinib + TACE for Unresectable Locally Advanced HCC
NCT05582109Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 36 months. Status: unknown.
02
Drugs
envafolimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05582109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582109.